Metagenomi Therapeutics Inc (MGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.17+0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MGX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenues | — | 25.2 | 52.3 | 44.8 | — |
| Operating Expenses & Income | |||||
| R&D Expenses | 88.6 | 94.4 | 109.2 | 94.4 | — |
| Operating Income | (100.6) | (96.0) | (88.9) | (78.5) | — |
| Earnings from Continuing Operations | |||||
| Interest & Investment Income | 6.9 | 9.5 | 14.7 | 15.5 | — |
| Other Non-Operating Income / Expenses | 6.9 | 8.1 | 5.3 | 18.3 | — |
| Asset Writedown | — | — | 1.0 | 0.0 | — |
| EBT, Incl. Unusual Items | (93.7) | (87.9) | (83.6) | (60.2) | — |
| Income Tax Expense | — | (0.1) | (5.5) | 8.0 | — |
| Net Income | |||||
| Net Income | (93.5) | (87.9) | (78.1) | (68.3) | — |
| Per Share | |||||
| Basic EPS | (2.48) | (2.36) | (2.36) | (20.05) | — |
| Diluted EPS | (2.48) | (2.36) | (2.36) | (20.05) | — |
| Basic Weighted Avg Shares | 37.7 | 37.3 | 33.0 | 3.4 | — |
| Diluted Weighted Avg Shares | 37.7 | 37.3 | 33.0 | 3.4 | — |
| Supplemental | |||||
| EBIT | (100.6) | (96.0) | (88.9) | (78.5) | — |
| Effective Tax Rate | — | — | — | -13.3% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.